Medikit (7749) Q4 2026 earnings summary

Executive summary

• Net sales increased by 5.4% year-over-year to ¥23,781 million for the fiscal year ended March 31, 2026.

• Operating profit declined 4.8% year-over-year to ¥4,272 million, while ordinary profit decreased 3.7% to ¥4,484 million.

• Profit attributable to owners of parent was ¥3,006 million, nearly flat year-over-year.

• Comprehensive income rose 10.2% year-over-year to ¥3,392 million.

Financial highlights

• Gross profit increased to ¥9,007 million from ¥8,668 million year-over-year.

• Operating margin declined to 18.0% from 19.9% year-over-year.

• Cash and cash equivalents at period end rose to ¥18,652 million from ¥17,059 million.

• Net assets per share increased to ¥3,231.16 from ¥3,089.58 year-over-year.

Outlook and guidance

• For the fiscal year ending March 31, 2027, net sales are forecast to rise 8.5% to ¥25,800 million.

• Operating profit is projected to grow 0.6% to ¥4,300 million, with profit attributable to owners of parent expected to decrease 5.2% to ¥2,850 million.

• Annual dividend per share is forecast at ¥100.00, with a payout ratio of 50.8%.